Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -15.95 | 69.74 | 82.97 | |
| Graham Fair Price | -34.31 | 4.44 | 6.77 | |
| PEG | 32329.29 | -0.84 | < 0.005 | |
| Price/Book | 2.60 | 3.35 | 3.27 | |
| Price/Cash Flow | -95.12 | 140.96 | -2886.30 | |
| Prices/Earnings | 121.01 | 47.81 | 21.63 | |
| Price/Sales | 8.78 | 16.78 | 15.43 | |
| Price/FCF | -95.12 | 140.96 | -2886.30 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.49 | 0.95 | 0.95 | |
| Operating Margin | -59.37 | 0.07 | 0.17 | |
| ROA | -54.21 | 0.01 | 0.03 | |
| ROE | 0.04 | 0.02 | -53.58 | |
| ROIC | 0.03 | < 0.005 | -64.95 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.06 | < 0.005 | 1166.68 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 5.65 | -0.64 | -88.68 | |
| EPS QOQ | 83.85 | -0.57 | -99.32 | |
| FCF QOQ | -1.11 | 20.75 | 1770.55 | |
| Revenue QOQ | 0.02 | -0.11 | 592.56 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 71.67 | 89.36 | 24.69 | |
| Days Sales Outstanding (DSO) | 44.55 | 50.92 | 14.31 | |
| Inventory Turnover | 1.26 | 1.01 | -19.80 | |
| Debt/Capitalization | 0.09 | 0.08 | -2.39 | |
| Quick Ratio | 3.13 | 3.23 | 3.23 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 7.34 | 7.08 | -3.59 | |
| Cash | 3.23 | 3.20 | -0.73 | |
| Capex | -0.04 | -0.06 | -42.05 | |
| Free Cash Flow | < 0.005 | 0.17 | 1925.41 | |
| Revenue | 1.55 | 1.41 | -9.07 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad